CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 560 enrolled
Drug / intervention
Topical 85% trichloroacetic acid (TCA) +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02615860
NCT02615860N/ACompleted

Efficacy and Safety of Topical Trichloroacetic Acid vs. Electrocautery for the Treatment of Anal Intraepithelial Neoplasia in HIV-positive Patients (TECAIN) - a Randomized Controlled Trial

University Hospital, Essen·interventional·Posted Nov 26, 2015·Updated Nov 8, 2022

In Brief

A clinical study evaluating Topical 85% trichloroacetic acid (TCA) and Surgical electrocautery (ECA) for Anal Intraepithelial Neoplasia (AIN) in HIV-infected Patients. Completed, enrolled 560 participants across 1 site.

Detailed Summary

Comparative evaluation of efficacy and safety of high-resolution anoscopy (HRA)-guided topical treatment (trichloroacetic acid, TCA) vs. surgical treatment (electrocautery, ECA) in HIV-positive patients for human papillomavirus (HPV)- induced AIN, an anal cancer precursor. The primary hypothesis is that cost-saving and simple TCA treatment is non-inferior to the current best option therapy with ECA. TCA treatment would also be possible in the normal setting of a doctor´s office without extensive specialization and without complex technical equipment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesGermany
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 26, 2015
Enrollment StartNov 1, 2015
Primary CompletionMar 31, 2020
Study CompletionDec 31, 2021
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 10.6 years ago

Interventions

Topical 85% trichloroacetic acid (TCA)other

In the experimental intervention arm, all visible lesions are treated with 85% TCA by dipping the wooden stick end of a cotton swab into a cup containing TCA. The stick end is saturated with TCA and is inserted through the anoscope and directed to the lesion under HRA guidance. TCA is applied to the lesion repeatedly until the lesion changes to a dense white colour. Each TCA application session is followed by another appointment four weeks later, where the clinician re-evaluates the lesions of the patient and determines whether a next TCA application is necessary up to a maximum of four times

Surgical electrocautery (ECA)procedure

In the control arm, HRA-guided ECA, is performed every 4 weeks up to a maximum of four times. All visible lesions are ablated at every visit. Bleeding from small vessels can be stopped by ECA. Patients undergo local anaesthesia if necessary